{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:06:11Z","timestamp":1772136371266,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79070-2","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T07:35:54Z","timestamp":1731310554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of different nephrectomy types on M0 renal cell carcinoma outcomes in a propensity score matching and deep learning study"],"prefix":"10.1038","volume":"14","author":[{"given":"Shuhong","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"79070_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","volume":"16","author":"WM Linehan","year":"2019","unstructured":"Linehan, W. M. & Ricketts, C. J. The Cancer Genome Atlas of renal cell carcinoma: Findings and clinical implications. Nat. Rev. Urol. 16, 539\u2013552 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"79070_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. Ca-a Cancer Journal for Clinicians 73, 17\u201348 (2023).","journal-title":"Ca-a Cancer Journal for Clinicians"},{"key":"79070_CR3","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","volume":"103","author":"J Ferlay","year":"2018","unstructured":"Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 103, 356\u2013387 (2018).","journal-title":"Eur. J. Cancer"},{"key":"79070_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.euo.2018.08.023","volume":"2","author":"HD Patel","year":"2019","unstructured":"Patel, H. D. et al. Clinical stage migration and survival for renal cell carcinoma in the United States. European Urology Oncology 2, 343\u2013348 (2019).","journal-title":"European Urology Oncology"},{"key":"79070_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41585-022-00592-3","volume":"19","author":"A Ingels","year":"2022","unstructured":"Ingels, A. et al. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat. Rev. Urol. 19, 391\u2013418 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"79070_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","volume":"82","author":"B Ljungberg","year":"2022","unstructured":"Ljungberg, B. et al. European association of urology guidelines on renal cell carcinoma: The 2022 update. Eur. Urol. 82, 399\u2013410 (2022).","journal-title":"Eur. Urol."},{"key":"79070_CR7","doi-asserted-by":"crossref","unstructured":"Grabbert M, Grosu AL, Zamboglou C, Gratzke C: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. European Urology 2022, 81:622\u2013622.","DOI":"10.1016\/j.eururo.2022.02.017"},{"key":"79070_CR8","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(23)00913-3","volume":"402","author":"CW Ryan","year":"2023","unstructured":"Ryan, C. W. et al. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): A double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 402, 1043\u20131051 (2023).","journal-title":"Lancet"},{"key":"79070_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamaoncol.2019.4716","volume":"6","author":"N Singla","year":"2020","unstructured":"Singla, N. Progress toward precision medicine in frontline treatment of metastatic renal cell carcinoma. JAMA Oncol. 6, 25\u201326 (2020).","journal-title":"JAMA Oncol."},{"key":"79070_CR10","doi-asserted-by":"publisher","first-page":"102528","DOI":"10.1016\/j.ctrv.2023.102528","volume":"115","author":"C Ciccarese","year":"2023","unstructured":"Ciccarese, C. et al. Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario. Cancer Treat. Rev. 115, 102528 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"79070_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.874427","author":"C Zhanghuang","year":"2022","unstructured":"Zhanghuang, C. et al. Development and validation of a nomogram to predict cancer-specific survival in elderly patients with papillary renal cell carcinoma. Front. Public Health https:\/\/doi.org\/10.3389\/fpubh.2022.874427 (2022).","journal-title":"Front. Public Health"},{"key":"79070_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers, A. J. & Elkin, E. B. Decision curve analysis: A novel method for evaluating prediction models. Med. Decis. Making 26, 565\u2013574 (2006).","journal-title":"Med. Decis. Making"},{"issue":"8","key":"79070_CR13","doi-asserted-by":"publisher","first-page":"110055","DOI":"10.1016\/j.celrep.2021.110055","volume":"37","author":"R Elias","year":"2021","unstructured":"Elias, R. et al. A renal cell carcinoma tumorgraft platform to advance precision medicine. Cell Reports 37(8), 110055 (2021).","journal-title":"Cell Reports"},{"issue":"10","key":"79070_CR14","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1021\/acs.molpharmaceut.2c00034","volume":"19","author":"QY Wu","year":"2022","unstructured":"Wu, Q. Y., Huang, G., Wei, W. J. & Liu, J. J. Molecular imaging of renal cell carcinoma in precision medicine. Mol. Pharm. 19(10), 3457\u20133470 (2022).","journal-title":"Mol. Pharm."},{"key":"79070_CR15","first-page":"340","volume":"46","author":"A Luis-Cardo","year":"2022","unstructured":"Luis-Cardo, A. et al. Laparoscopic nephron sparing surgery and radical nephrectomy in cT1 renal tumors. Comparative analysis of complications and survival. Actas Urologicas Espanolas 46, 340\u2013347 (2022).","journal-title":"Actas Urologicas Espanolas"},{"key":"79070_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.eururo.2016.08.060","volume":"71","author":"MC Mir","year":"2017","unstructured":"Mir, M. C. et al. Partial nephrectomy versus radical nephrectomy for clinical T1b and T2 renal tumors: A systematic review and meta-analysis of comparative studies. Eur. Urol. 71, 606\u2013617 (2017).","journal-title":"Eur. Urol."},{"key":"79070_CR17","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1089\/end.2023.0173","volume":"37","author":"TE Stout","year":"2023","unstructured":"Stout, T. E., Gellhaus, P. T., Tracy, C. R. & Steinberg, R. L. Robotic partial radical nephrectomy for clinical T3a tumors: A narrative review. J. Endourol. 37, 978\u2013985 (2023).","journal-title":"J. Endourol."},{"key":"79070_CR18","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1245\/s10434-020-08813-y","volume":"28","author":"N Liu","year":"2021","unstructured":"Liu, N. et al. Nephron-sparing surgery for adult Xp11.2 translocation renal cell carcinoma at clinical t1 stage: A multicenter study in China. Ann. Surg. Oncol. 28, 1238\u20131246 (2021).","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"79070_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.eururo.2023.02.016","volume":"84","author":"R Hannan","year":"2023","unstructured":"Hannan, R. et al. Phase 2 trial of stereotactic ablative radiotherapy for patients with renal cancer. Eur. Urol. 84(3), 275\u2013286 (2023).","journal-title":"Eur. Urol."},{"key":"79070_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ejso.2022.09.022","volume":"49","author":"SD Pandolfo","year":"2023","unstructured":"Pandolfo, S. D. et al. Percutaneous thermal ablation for cT1 renal mass in solitary kidney: A multicenter trifecta comparative analysis versus robot-assisted partial nephrectomy. Ejso 49, 486\u2013490 (2023).","journal-title":"Ejso"},{"key":"79070_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16520","author":"M Ali","year":"2024","unstructured":"Ali, M. et al. Salvage stereotactic ablative body radiotherapy after thermal ablation of primary kidney cancer. BJU Int. https:\/\/doi.org\/10.1111\/bju.16520 (2024).","journal-title":"BJU Int."},{"key":"79070_CR22","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00330-022-09211-6","volume":"33","author":"X Wu","year":"2023","unstructured":"Wu, X., Uhlig, J., Shuch, B. M., Uhlig, A. & Kim, H. S. Cost-effectiveness of minimally invasive partial nephrectomy and percutaneous cryoablation for cT1a renal cell carcinoma. Eur. Radiol. 33, 1801\u20131811 (2023).","journal-title":"Eur. Radiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79070-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79070-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79070-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T07:16:19Z","timestamp":1731654979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79070-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79070"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79070-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4480345\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Patient consent was waived due to this article using data from the SEER database, which are publicly available deidentified patient data from the National Cancer Institute (NCI), USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"27571"}}